High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML)

Graf, M.; Reif, S.; Hecht, K.; Pelka-Fleischer, R.; Kroell, T.; Pfister, K.; Schmetzer, H.
May 2005
Annals of Hematology;May2005, Vol. 84 Issue 5, p287
Academic Journal
Costimulatory molecules such as lymphocyte function-associated antigen (LFA)-1 (CD11a), LFA-3 (CD58), intercellular adhesion molecule (ICAM)-1 (CD54), neuronal cell adhesion molecule (NCAM) (CD56), B7-1 (CD80), or B7-2 (CD86) are important regulatory elements in healthy immunological cascades, but their role in acute myeloid leukemia (AML) has only been rarely investigated. We studied their expression on mononuclear bone marrow (BM) cells from 105 patients with AML at initial diagnosis and evaluated their prognostic significance. Fluorescence-activated cell sorter (FACS) analyses were performed using antibodies directly conjugated with fluorescein. A BM sample was considered positive if more than 20% of the cells in the blast containing gate expressed the respective marker. The surface expression of CD11a (27 of 29 cases positive with an average of 71% positive blasts; 27+/29, 71%), CD54 (23+/33, 37%), CD56 (24+/93, 20%), CD58 (29+/29, 95%), CD80 (13+/28, 30%), and CD86 (19+/29, 39%) was measured. The expression of these markers in different French-American-British (FAB) classification types (M0-M5) was heterogeneous, except for CD56, which showed a higher proportion of positive cells in monocytic subtypes of AML. In addition, cases with a “poor risk” karyotype as well as patients succumbing to “early death” after double induction therapy according to the AML Cooperative Group (CG) protocol were characterized by a high expression of CD56. Relapse-free survival analyses demonstrated that patients with more than 8% CD56+ cells in the BM relapsed significantly sooner. CD54 was preferentially expressed in AML M4eo and in addition in “favorable” cytogenetic risk groups and in cases that had responded to AML-CG therapy. Only very high proportions (>60%) of CD54+ cells were associated with a lower probability for relapse-free survival. CD80 and CD86 expressions were similar in all FAB types. Patients who had responded to AML-CG therapy showed higher CD80 proportions and lower CD86 proportions compared to the “nonresponder” group. Whereas cases with more than 15% CD80+ cells had a significantly lower probability for relapse-free survival, only cases with more than 65% CD86+ were characterized by a significantly lower probability for relapse-free survival. Expression profiles of CD11a and CD58 were not associated with specific FAB types or prognostically relevant groups. We can conclude: (1) Expression of costimulatory molecules in AML is very variable. This reflects the great diversity of immunophenotypes in AML. (2) CD56 is mainly expressed in monocytic subtypes of AML. CD56+ subtypes of AML seem to be a separate entity with a worse prognosis independent of the karyotype. (3) High expression of some costimulatory molecules correlates with a worse prognosis concerning relapse-free survival times.


Related Articles

  • Is there any genetic susceptibility to acute promyelocytic leukemia? Thomas, X // Leukemia (08876924);Dec2000, Vol. 14 Issue 12, p2324 

    Focuses on a distinct subtype of acute myelogenous leukemia called Acute promyelocytic leukemia (APL). Identification of patients with a high risk of relapse of disease; Questionability of genetic susceptibility to APL; Case studies related to the medical condition.

  • Etiology of acute myeloid leukemia following intensive therapy for AML – relapse, secondary disease or bad luck? Braess, J; Schoch, C; Fiegl, M; Schmid, C; Hiddemann, W; Kolb, H-J // Leukemia (08876924);Dec2002, Vol. 16 Issue 12, p2459 

    Leukemia (2002) 16, 2459–2462. doi:10.1038/sj.leu.2402772

  • Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Charrad, Rachida-Sihem; Li, Yue; Delpech, Bertrand; Balitrand, Nicole; Clay, Denis; Jasmin, Claude; Chomienne, Christine; Smadja-Joffe, Florence // Nature Medicine;Jun99, Vol. 5 Issue 6, p669 

    Blockage in myeloid differentiation characterizes acute myeloid leukemia (AML); the stage of the blockage defines distinct AML subtypes (AML½ to AMLS). Differentiation therapy in AML has recently raised interest because the survival of AML3 patients has been greatly improved using the...

  • Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. Ritchie, David S.; Neeson, Paul J.; Khot, Amit; Peinert, Stefan; Tai, Tsin; Tainton, Kellie; Chen, Karen; Shin, Mandy; Wall, Dominic M.; Hönemann, Dirk; Gambell, Peter; Westerman, David A.; Haurat, Javier; Westwood, Jennifer A.; Scott, Andrew M.; Kravets, Lucy; Dickinson, Michael; Trapani, Joseph A.; Smyth, Mark J.; Darcy, Phillip K. // Molecular Therapy;Nov2013, Vol. 21 Issue 11, p2122 

    In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3...

  • Syndromes myélodysplasiques: Mise au point. Gardin, C.; Fenaux, P. // Oncologie;mai2006, Vol. 8 Issue 4, p362 

    Myelodysplastic syndromes (MDS) are hematopoeitic clonal disorders of rapidly increasing incidence above 60 years of age. The mechanisms of the disease are complex ones and not yet fully understood. Increased apoptosis of bone marrow cells and genetic instability are important characteristics of...

  • HES1 activation suppresses proliferation of leukemia cells in acute myeloid leukemia. Tian, Chen; Yu, Yong; Jia, Yongsheng; Zhu, Lei; Zhang, Yizhuo // Annals of Hematology;Sep2015, Vol. 94 Issue 9, p1477 

    Although aberrant Notch activation contributes to leukemogenesis in T cells, the role of Notch pathway in acute myeloid leukemia (AML) remains controversial. To address this issue, we compared the expression levels of its downstream effector HES1 and p21 in bone marrow mononuclear cells (BMNCs)...

  • Prognosis of patients with a second relapse of acute myeloid leukemia. Stoiser, B; Knöbl, P; Fonatsch, C; Haas, O A; Mitterbauer, G; Weltermann, A; Geissler, K; Valent, P; Sperr, W; Pabinger, I; Lechner, K; Jaeger, U // Leukemia (08876924);Dec2000, Vol. 14 Issue 12, p2059 

    Recurrence of the disease is the major problem in the treatment of acute myeloid leukemia (AML). The majority of patients who achieve a second remission will ultimately relapse. In this retrospective single-center study, we have analyzed the outcome of patients with a second relapse and tried to...

  • The State of Differentiation of Cultured Human Keratinocytes Determines the Level of Intercellular Adhesion Molecule-1 (ICAM-1) Expression Induced by γ Interferon. Kashihara-Sawami, Mari; Norris, David A. // Journal of Investigative Dermatology;May92, Vol. 98 Issue 5, p741 

    Inducing the expression of ICAM-1(CD54) on the surface of epidermal keratinocytes is an important step, in initiating leukocyte interaction with the epidermis. We studied tile effect of keratinocyte differentiation and of drugs used to treat epidermal inflammation on the induction of this...

  • Multi-analytical evaluation of serum levels of cytokines and adhesion molecules in patients treated for acute myeloid leukemia using biochip array technology. Horacek, Jan M.; Vasatova, Martina; Kupsa, Tomas; Jebavy, Ladislav; Zak, Pavel // Biomedical Papers of the Medical Faculty of Palacky University i;Dec2013, Vol. 157 Issue 4, p277 

    Aims. Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients treated for acute myeloid leukemia (AML) using biochip array technology. This approach allows multi-analytical determination from a single sample. Methods. A total of 15 AML patients were studied. Blood samples...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics